Our platform

Galvanis is building a programmable bioelectric regeneration platform.

OUR MODEL

Identify repair settings where endogenous control signals are measurable
Modulate those signals with druggable interventions, and advance only candidates that clear predefined pharmacodynamic and functional gates before serious downstream spend.
Lead with a clear win
Ocular surface repair is the lead application because the biology is accessible, the readouts are objective, and the development path is efficient.
Scale across indications
After corneal proof of concept, the same logic can extend into adjacent impaired-healing ocular surface indications.

We start with ocular surface repair because it offers fast, interpretable readouts and a clear path to clinical value.

Epithelial tissues maintain voltage gradients and ion transport that shape cell migration. In impaired healing, those signals can be reduced; cells lose directional guidance and closure stalls.

Our approach is to restore the signal, then verify it with pharmacodynamics (PD): ΔTEP / Δion flux. This turns bioelectricity from an observation into an engineering variable.

Bioelectricity is measurable

We instrument pharmacodynamics, pre‑specify gates, and iterate. For OcuRegen™, we screen candidates with PD readouts (ΔTEP / Δion flux) and functional closure assays ex vivo, then validate in vivo once the mechanism‑to‑effect link is established. This is how a platform becomes repeatable.

Building like an engineering company

See the science

Ocular surface repair is the fastest path to a clear, mechanistic clinical signal.

PCED is an orphan‑scale problem (~100k US cases/year) with high unmet need.
When defects don’t close, care escalates quickly to procedures.
Local dosing enables high exposure with minimal systemic burden.
Closure is an objective endpoint; well-suited for PD‑gated de‑risking.

Why start with the cornea

Start with PCED to establish the mechanistic link between PD and closure. Then expand the same approach into neurotrophic keratitis and other impaired‑healing ocular surface settings.